In conclusion, this study showed that 12 weeks of Eriomin supplementation, at 200 mg/d, resulted in a reduction in hyperglycemia (−5%), and a diminished inflammatory response, by decreasing blood serum markers IL-6 (−14%) and TNF-α (−20%). This evidence concerns the gene IL6 and Hyperglycemia.